{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:40:13Z","timestamp":1781534413613,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Betaalbaar beter; Radboud Oncologie Fonds - ROF1907; Paul Speth Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,1,31]]},"DOI":"10.1038\/s41416-025-03243-7","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T12:53:19Z","timestamp":1761915199000},"page":"306-316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study"],"prefix":"10.1038","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9181-1359","authenticated-orcid":false,"given":"Iris S. H.","family":"Kloots","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5635-919X","authenticated-orcid":false,"given":"Peter H. J.","family":"Slootbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie H.","family":"Tolmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"van Wilpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minke","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd","family":"van Helvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2666-1742","authenticated-orcid":false,"given":"Leonie I.","family":"Kroeze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolique A.","family":"van Ipenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Gr\u00fcnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Marleen","family":"Kets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1290-1474","authenticated-orcid":false,"given":"Marjolijn J. L.","family":"Ligtenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Nagarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"F\u00fctterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce M.","family":"van Dodewaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"van Voorthuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederiek","family":"Terheggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tineke J.","family":"Smilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8274-7797","authenticated-orcid":false,"given":"Jack A.","family":"Schalken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiko J.","family":"Bloemendal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winald R.","family":"Gerritsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4794-1831","authenticated-orcid":false,"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the PROMPT collaboration network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce M.","family":"van Dodewaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"van Voorthuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"3243_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1405095.","journal-title":"N Engl J Med"},{"key":"3243_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1213755.","journal-title":"N Engl J Med"},{"key":"3243_CR3","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 2020;382:2091\u2013102. https:\/\/doi.org\/10.1056\/NEJMoa1911440.","journal-title":"N Engl J Med"},{"key":"3243_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"3243_CR5","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41391-021-00344-1","volume":"24","author":"HM Westgeest","year":"2021","unstructured":"Westgeest HM, Kuppen MCP, van den Eertwegh AJM, de Wit R, Bergman AM, van Moorselaar RJA, et al. The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population. Prostate Cancer Prostat Dis. 2021;24:871\u20139. https:\/\/doi.org\/10.1038\/s41391-021-00344-1.","journal-title":"Prostate Cancer Prostat Dis"},{"key":"3243_CR6","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.1038\/s41467-019-13084-7","volume":"10","author":"LF van Dessel","year":"2019","unstructured":"van Dessel LF, van Riet J, Smits M, Zhu Y, Hamberg P, van der Heijden MS, et al. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. Nat Commun. 2019;10:5251 https:\/\/doi.org\/10.1038\/s41467-019-13084-7.","journal-title":"Nat Commun"},{"key":"3243_CR7","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/s43018-020-00141-0","volume":"1","author":"J Mateo","year":"2020","unstructured":"Mateo J, McKay R, Abida W, Aggarwal R, Alumkal J, Alva A, et al. Accelerating precision medicine in metastatic prostate cancer. Nat Cancer. 2020;1:1041\u201353. https:\/\/doi.org\/10.1038\/s43018-020-00141-0.","journal-title":"Nat Cancer"},{"key":"3243_CR8","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41391-020-00308-x","volume":"24","author":"T Sumiyoshi","year":"2021","unstructured":"Sumiyoshi T, Chi KN, Wyatt AW. Clinical implications of genomic alterations in metastatic prostate cancer. Prostate Cancer Prostat Dis. 2021;24:310\u201322. https:\/\/doi.org\/10.1038\/s41391-020-00308-x.","journal-title":"Prostate Cancer Prostat Dis"},{"key":"3243_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","volume":"5","author":"W Abida","year":"2019","unstructured":"Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 2019;5:471\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5801.","journal-title":"JAMA Oncol"},{"key":"3243_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-019-1600-x","volume":"574","author":"DL van der Velden","year":"2019","unstructured":"van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P, et al. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019;574:127\u201331. https:\/\/doi.org\/10.1038\/s41586-019-1600-x.","journal-title":"Nature"},{"key":"3243_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12967-022-03432-5","volume":"20","author":"\u00c5 Helland","year":"2022","unstructured":"Helland \u00c5, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, et al. Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. J Transl Med. 2022;20:225 https:\/\/doi.org\/10.1186\/s12967-022-03432-5.","journal-title":"J Transl Med"},{"key":"3243_CR12","doi-asserted-by":"publisher","unstructured":"Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KA, et al. Rationale and design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2018. Available from: https:\/\/doi.org\/10.1200\/PO.18.00122.","DOI":"10.1200\/PO.18.00122"},{"key":"3243_CR13","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","volume":"29","author":"PJ O\u2019Dwyer","year":"2023","unstructured":"O\u2019Dwyer PJ, Gray RJ, Flaherty KT, Chen AP, Li S, Wang V, et al. The NCI-MATCH trial: lessons for precision oncology. Nat Med. 2023;29:1349\u201357.","journal-title":"Nat Med"},{"key":"3243_CR14","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1158\/1078-0432.CCR-23-0983","volume":"30","author":"I Zhou","year":"2024","unstructured":"Zhou I, Plana D, Palmer AC. Tumor-specific activity of precision medicines in the NCI-MATCH trial. Clin Cancer Res. 2024;30:786\u201392.","journal-title":"Clin Cancer Res"},{"key":"3243_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2340\/1651-226X.2024.34885","volume":"63","author":"SF Haj Mohammad","year":"2024","unstructured":"Haj Mohammad SF, Timmer HJL, Zeverijn LJ, Geurts BS, Spiekman IAC, Verkerk K, et al. The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP). Acta Oncol. 2024;63:368\u201372.","journal-title":"Acta Oncol"},{"key":"3243_CR16","doi-asserted-by":"publisher","first-page":"113988","DOI":"10.1016\/j.ejca.2024.113988","volume":"202","author":"IAC Spiekman","year":"2024","unstructured":"Spiekman IAC, Zeverijn LJ, Geurts BS, Verkerk K, Haj Mohammad SF, van der Noort V, et al. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP). Eur J Cancer. 2024;202:113988.","journal-title":"Eur J Cancer"},{"key":"3243_CR17","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-21-1104","volume":"27","author":"H van der Wijngaart","year":"2021","unstructured":"van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, Zeverijn LJ, Roepman P, et al. Patients with biallelic BRCA1\/2 inactivation respond to olaparib treatment across histologic tumor types. Clin Cancer Res. 2021;27:6106\u201314.","journal-title":"Clin Cancer Res"},{"key":"3243_CR18","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1158\/1078-0432.CCR-21-3752","volume":"28","author":"LR Hoes","year":"2022","unstructured":"Hoes LR, van Berge Henegouwen JM, van der Wijngaart H, Zeverijn LJ, van der Velden DL, van de Haar J, et al. Patients with rare cancers in the Drug Rediscovery Protocol (DRUP) benefit from genomics-guided treatment. Clin Cancer Res. 2022;28:1402\u201311.","journal-title":"Clin Cancer Res"},{"key":"3243_CR19","unstructured":"NCCN Guidelines Prostaat 2022.pdf."},{"key":"3243_CR20","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31:1491\u2013505. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.014.","journal-title":"Ann Oncol"},{"key":"3243_CR21","doi-asserted-by":"publisher","unstructured":"Tao DL, Bailey S, Beer TM, Foss E, Beckett B, Fung A, et al. Molecular testing in patients with castration-resistant prostate cancer and its impact on clinical decision making. JCO Precision Oncol. 2017:1\u201311. Available from: https:\/\/doi.org\/10.1200\/PO.16.00067.","DOI":"10.1200\/PO.16.00067"},{"key":"3243_CR22","doi-asserted-by":"publisher","first-page":"27145","DOI":"10.18632\/oncotarget.16057","volume":"8","author":"AH Bryce","year":"2017","unstructured":"Bryce AH, Egan JB, Borad MJ, Stewart AK, Nowakowski GS, Chanan-Khan A, et al. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. Oncotarget [Internet]. 2017;8:27145\u201354. https:\/\/doi.org\/10.18632\/oncotarget.16057.","journal-title":"Oncotarget [Internet]"},{"key":"3243_CR23","doi-asserted-by":"publisher","unstructured":"Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol. 2017 Jul;2017. Available from: https:\/\/doi.org\/10.1200\/PO.17.00029.","DOI":"10.1200\/PO.17.00029"},{"key":"3243_CR24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.mayocpiqo.2018.12.005","volume":"3","author":"RE Jimenez","year":"2019","unstructured":"Jimenez RE, Atwell TD, Sicotte H, Eckloff B, Wang L, Barman P, et al. A prospective correlation of tissue histopathology with nucleic acid yield in metastatic castration-resistant prostate cancer biopsy specimens. Mayo Clin Proc Innov Qual Outcomes. 2019;3:14\u201322.","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"3243_CR25","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.2967\/jnumed.119.241109","volume":"61","author":"AC de Jong","year":"2020","unstructured":"de Jong AC, Smits M, van Riet J, F\u00fctterer JJ, Brabander T, Hamberg P, et al. 68Ga-PSMA-Guided bone biopsies for molecular diagnostics in patients with metastatic prostate cancer. J Nucl Med. 2020;61:1607\u201314. https:\/\/doi.org\/10.2967\/jnumed.119.241109.","journal-title":"J Nucl Med"},{"key":"3243_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.euros.2022.11.011","volume":"49","author":"Mehra","year":"2023","unstructured":"Mehra, Kloots N, Vlaming I, Aluwini M, Dewulf S, Oprea-Lager DE E, et al. Genetic aspects and molecular testing in prostate cancer: a report from a Dutch Multidisciplinary Consensus Meeting. Eur Urol Open Sci. 2023;49:23\u201331.","journal-title":"Eur Urol Open Sci"},{"key":"3243_CR27","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41416-021-01663-9","volume":"126","author":"PHJ Slootbeek","year":"2022","unstructured":"Slootbeek PHJ, Kloots ISH, Smits M, van Oort IM, Gerritsen WR, Schalken JA, et al. Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer. Br J Cancer. 2022;126:907\u201316. https:\/\/doi.org\/10.1038\/s41416-021-01663-9.","journal-title":"Br J Cancer"},{"key":"3243_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1200\/JCO.2022.40.6_suppl.040","volume":"40","author":"ISH Kloots","year":"2022","unstructured":"Kloots ISH, Slootbeek PHJ, Smits M, van Helvert S, Kroeze LI, Kets M, et al. First results of the PROMPT trial: Precision oncology allocation in patients with early castration-resistant prostate cancer following routine molecular profiling. J Clin Oncol. 2022;40:40\u201340.","journal-title":"J Clin Oncol"},{"key":"3243_CR29","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","volume":"22","author":"JS de Bono","year":"2021","unstructured":"de Bono JS, Mehra N, Scagliotti GV, Castro E, Dorff T, Stirling A, et al. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet Oncol. 2021;22:1250\u201364. https:\/\/doi.org\/10.1016\/S1470-2045(21)00376-4.","journal-title":"Lancet Oncol"},{"key":"3243_CR30","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.23.00339","volume":"42","author":"J Mateo","year":"2024","unstructured":"Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and\/or BRCA2 in the PROfound Trial. JCO. 2024;42:571\u201383.","journal-title":"JCO"},{"key":"3243_CR31","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1038\/ncomms8505","volume":"6","author":"M Sedic","year":"2015","unstructured":"Sedic M, Skibinski A, Brown N, Gallardo M, Mulligan P, Martinez P, et al. Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence. Nat Commun. 2015;6:7505.","journal-title":"Nat Commun"},{"key":"3243_CR32","doi-asserted-by":"publisher","unstructured":"Smits M, Ekici K, Pamidimarri Naga S, van Oort IM, Sedelaar MJP, Schalken JA, et al. Prior PSMA PET-CT Imaging and Hounsfield unit impact on tumor yield and success of molecular analyses from bone biopsies in metastatic prostate cancer. Cancers. 2020 Dec 14;12. Available from: https:\/\/doi.org\/10.3390\/cancers12123756.","DOI":"10.3390\/cancers12123756"},{"key":"3243_CR33","unstructured":"VKGN-StOET. 14. Prostaatcarcinoom. 2023 [cited 2023 Jul 13]. Available from: https:\/\/vkgn.stoet.nl\/index.php?article_id=16."},{"key":"3243_CR34","doi-asserted-by":"publisher","first-page":"S1179","DOI":"10.1016\/j.annonc.2022.07.1523","volume":"33","author":"ISH Kloots","year":"2022","unstructured":"Kloots ISH, Kets M, Schuurs-Hoeijmakers J, Westdorp H, Coskunturk M, Bloemendal H, et al. 1391P Tumor-first mutation-specific risk approach to trigger germline testing in castration-resistant prostate cancer. Ann Oncol [Internet]. 2022;33:S1179.","journal-title":"Ann Oncol [Internet]"},{"key":"3243_CR35","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-21-3940","volume":"28","author":"M Hussain","year":"2022","unstructured":"Hussain M, Corcoran C, Sibilla C, Fizazi K, Saad F, Shore N, et al. Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). Clin Cancer Res. 2022;28:1518\u201330.","journal-title":"Clin Cancer Res"},{"key":"3243_CR36","doi-asserted-by":"publisher","unstructured":"Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evidence. 2022; 23;1:EVIDoa2200043. Available from: https:\/\/doi.org\/10.1056\/EVIDoa2200043.","DOI":"10.1056\/EVIDoa2200043"},{"key":"3243_CR37","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402:291\u2013303.","journal-title":"Lancet"},{"key":"3243_CR38","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1094\u2013108.","journal-title":"Lancet Oncol"},{"key":"3243_CR39","doi-asserted-by":"publisher","first-page":"563.e1","DOI":"10.1016\/j.clgc.2021.07.014","volume":"19","author":"J Cham","year":"2021","unstructured":"Cham J, Venkateswaran AR, Bhangoo M. Targeting the PI3K-AKT-mTOR pathway in castration resistant prostate cancer: A review article. Clin Genitourin Cancer. 2021;19:563.e1\u2013563.e7. https:\/\/doi.org\/10.1016\/j.clgc.2021.07.014.","journal-title":"Clin Genitourin Cancer"},{"key":"3243_CR40","unstructured":"de Bono JS, He M, Shi Z, Nowicka M, Bracarda S, Sternberg CN, et al. Final overall survival and molecular data associated with clinical outcomes in patients receiving ipatasertib and abiraterone in the phase 3 IPATential150 trial. Eur Urol. 2025; Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0302283824027714."},{"key":"3243_CR41","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.eururo.2022.05.019","volume":"82","author":"SJ Crabb","year":"2022","unstructured":"Crabb SJ, Griffiths G, Dunkley D, Downs N, Ellis M, Radford M, et al. Overall survival update for patients with metastatic castration-resistant prostate cancer treated with capivasertib and docetaxel in the phase 2 ProCAID clinical trial. Eur Urol. 2022;82:512\u20135.","journal-title":"Eur Urol"},{"key":"3243_CR42","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.eururo.2020.04.058","volume":"78","author":"C Herberts","year":"2020","unstructured":"Herberts C, Murtha AJ, Fu S, Wang G, Sch\u00f6nlau E, Xue H, et al. Activating AKT1 and PIK3CA mutations in metastatic castration-resistant prostate cancer. Eur Urol. 2020;78:834\u201344.","journal-title":"Eur Urol"},{"key":"3243_CR43","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1158\/1535-7163.MCT-19-0936","volume":"19","author":"R Adelaiye-Ogala","year":"2020","unstructured":"Adelaiye-Ogala R, Gryder BE, Nguyen YTM, Alilin AN, Grayson AR, Bajwa W, et al. Targeting the PI3K\/AKT pathway overcomes enzalutamide resistance by inhibiting induction of the glucocorticoid receptor. Mol Cancer Ther [Internet]. 2020;19:1436\u201347. https:\/\/aacrjournals.org\/mct\/article\/19\/7\/1436\/92860\/Targeting-the-PI3K-AKT-Pathway-OvercomesJul.","journal-title":"Mol Cancer Ther [Internet]"},{"key":"3243_CR44","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/s41416-024-02614-w","volume":"130","author":"C Eberlein","year":"2024","unstructured":"Eberlein C, Williamson SC, Hopcroft L, Ros S, Moss JI, Kerr J, et al. Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. Br J Cancer [Internet]. 2024;130:1377\u201387.","journal-title":"Br J Cancer [Internet]"},{"key":"3243_CR45","doi-asserted-by":"crossref","unstructured":"Tortorella E, Giantulli S, Sciarra A, Silvestri I. AR and PI3K\/AKT in prostate cancer: A tale of two interconnected pathways. Int J Mol Sci. 2023;24:2046.","DOI":"10.3390\/ijms24032046"},{"key":"3243_CR46","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","volume":"35","author":"D Olmos","year":"2024","unstructured":"Olmos D, Lorente D, Alameda D, Cattrini C, Romero-Laorden N, Lozano R, et al. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes. Ann Oncol. 2024;35:458\u201372.","journal-title":"Ann Oncol"},{"key":"3243_CR47","unstructured":"van Wilpe S, Kloots ISH, Slootbeek PHJ, den Brok M, Westdorp H, Franken MD, et al. Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial. Ann Oncol. 2024 Sep 16; Available from: https:\/\/pdf.sciencedirectassets.com\/321639\/AIP\/1-s2.0-S0923753424039991\/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEM%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJIMEYCIQCAyLz9WEB2TOA83Rr5VH%2Fu6CkbquZgbSgtoaA5141UXAIhAIbJ9ytHOEDomPEXvtshl1Bk4ATtRGiE%2FnYPB%2B7I0hDUKrIFCCgQBRoMMDU5MDAzNTQ2ODY1IgwCoXEhS5nekscA%2BoYqjwVI51o3nbWBxPI7O4D%2FHG3r6K4Y9OyNhbFQjxk9%2F8ADKijGEFfI%2FMd6AC3E5lIe88SnWlnfkt4bcnhOxJ9mPr6HrKECc2thROWLQVGduqTmCFo6lbUMTj16gX2p2GiyIu3cVws4Vf2LYXv9%2Fo4LXm4UvLvc%2BPehnb83oJjJgfrk28vydLSW0GQCKXoaIFF5zu3ddxxS5oJ6HUlQRan9F9%2FgJroleS%2BFE6PbVOn%2BCAloNZ06MbPyPQFxW%2BzPztK3EYJbxb%2BVe9K7OAYHGxRZ5gA%2BFKhGbAVNP6pfUVbdwb%2Bl2LCLSScpSjWeFbBX6EJC%2BCXMZwiwFEsmU8K04tx%2FQbkc8CAGJE9bPs5G6jJXd7Cplv%2B1rL23RgVe12nmfgIaFGvtjHFN%2BEo5wuEIWn693oz3x8yCmhkPNEMcTo7VMyetMXVcocyLe0PaXhUxdnvVYQpKMdiNwNmjR3%2BWzUloUEvVNTEJCuLldh4DrYcpwz6uZmuL%2BFx7oQvL9NzIXlxFUbz62W1U7czPOV9QtmUMjElBsd7Ub%2FRbzR%2B88DgFbhzbZOZ1MVtr9VWVfwGqyprqTJnFpA%2BO4VrobmpljXRKk%2B%2BYwSo8hJMlspH7ZHlbxWEmSdMhPwaDwnNPrFf4xYrFYsx1lEB0ZcywwCFdHcDt0HZI0pETFb4EKPnOU%2BUmlmqPchri%2FbeSmOJ5aO5hdaDgOW%2FrnCZj34mQo%2FNrv9EficBn7nRw8NTD12CYPZr07cYQeq9PmeJEc4em31zCf0DJ%2BwTtYzcmVzKB%2FbqH71Rh5lg0NEQx%2FV%2FRy%2BFa%2BUe38hTUx%2FSPVZBIaJl2AB2%2FQpBR6WmpKC6nTDhJcra3o91EJEtRXgOT8Yj67sg5v0%2F0FYNFMKX%2BjbgGOrAB%2FVvmCMctG7cmeAZ8H3QXLioevEV3X3PCvpN8rfl8wE8jKgHug6uOgP1dOv0TmTvu36z0ljkmfiNJTSEiOt4Ya9XPb%2F2x2MT%2BfPm2kmShB5aGqO4V2%2BBmUlGf3RbPcWEc49%2B4mtt1m9Z%2F6iQd4PLfQtgxVjAFtVafM%2Bc22YUJ5cWF9Xh0SZp73%2BGjraPUJ8Giz2KctuneVQdgTRfgsTW4YkC0EsTdd0UPDwQ9i6sh74o%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20241007T074503Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTY53EPDLYE%2F20241007%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=4b60c36a9e1d04fd54a21e4c58250e4e8527410b0866e0d77054abb87e28d7b7&hash=dabdb362144c7632f76395f91755139d839d97692a4de6bbe6144558be8cd88c&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S0923753424039991&tid=spdf-9b49e526-2d16-413e-9eaf-a8bb1d572964&sid=8b4a9c087d9d6646b85b2da4e5c53e090f8egxrqb&type=client&tsoh=d3d3LnNjaWVuY2VkaXJlY3QuY29t&ua=140858070a015057010a&rr=8cec44fe09d00b04&cc=nl."},{"key":"3243_CR48","doi-asserted-by":"publisher","unstructured":"Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, et al. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J Natl Cancer Inst. 2017;109. Available from: https:\/\/doi.org\/10.1093\/jnci\/djx118.","DOI":"10.1093\/jnci\/djx118"},{"key":"3243_CR49","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","volume":"33","author":"J Pascual","year":"2022","unstructured":"Pascual J, Attard G, Bidard F-C, Curigliano G, De Mattos-Arruda L, Diehn M, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022;33:750\u201368.","journal-title":"Ann Oncol"},{"key":"3243_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2350","volume":"7","author":"MT Schweizer","year":"2021","unstructured":"Schweizer MT, Sivakumar S, Tukachinsky H, Coleman I, De Sarkar N, Yu EY, et al. Concordance of DNA repair gene mutations in paired primary prostate cancer samples and metastatic tissue or cell-free DNA. JAMA Oncol. 2021;7:1\u20135. https:\/\/doi.org\/10.1001\/jamaoncol.2021.2350.","journal-title":"JAMA Oncol"},{"key":"3243_CR51","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1503747.","journal-title":"N Engl J Med"},{"key":"3243_CR52","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s13629-020-00282-y","volume":"10","author":"MGEM Ausems","year":"2020","unstructured":"Ausems MGEM, Kiemeney LALM. Genetisch onderzoek bij prostaatkanker: nieuwe ontwikkelingen. Tijdschr voor Urol. 2020;10:30\u20135. https:\/\/doi.org\/10.1007\/s13629-020-00282-y.","journal-title":"Tijdschr voor Urol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03243-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03243-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03243-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T13:54:16Z","timestamp":1768917256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03243-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,31]]}},"alternative-id":["3243"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03243-7","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MJL received consulting fees from GlaxoSmithKline B.V., Janssen-Cilag B.V., AstraZeneca; received honoraria for lectures: AstraZeneca, Janssen, Roche, MSD, Pfizer. All payments to Radboudumc. WRG is a member of the advisory boards of Astellas, Coretag holding AG, Merck Sharp and Dohme, and Novartis; received personal fees for coaching activities by Bayer; and is member of the board of directors of ORCA therapeutic B.V. NM received consultancy fees from Astellas Pharma, AstraZeneca, Bayer, Janssen-Cilag, Johnson & Johnson, Merck Sharp and Dohme, and Pfizer; and research funding (all paid to the institution) from Astellas Pharma, AstraZeneca\/Merck, Bristol Myers Squibb Foundation, and Janssen-Cilag. All other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The trial was conducted in accordance with the principles of the Declaration of Helsinki and classified by the medical ethical committee of \u201cCommissie Mensgebonden Onderzoek\u201d (CMO) regio Arnhem-Nijmegen. No ethics approval was needed for this study. All patients provided written informed consent. The study is registered in ClinicalTrials.gov under the number NCT04746300.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}